KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Non Operating Income (2019 - 2025)

Historic Non Operating Income for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to -$8.5 million.

  • GoodRx Holdings' Non Operating Income rose 3070.35% to -$8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.2 million, marking a year-over-year increase of 1391.85%. This contributed to the annual value of -$34.4 million for FY2024, which is 2037.81% down from last year.
  • Per GoodRx Holdings' latest filing, its Non Operating Income stood at -$8.5 million for Q3 2025, which was up 3070.35% from -$7.2 million recorded in Q2 2025.
  • GoodRx Holdings' 5-year Non Operating Income high stood at -$5.8 million for Q1 2022, and its period low was -$12.3 million during Q3 2024.
  • For the 5-year period, GoodRx Holdings' Non Operating Income averaged around -$7.1 million, with its median value being -$6.6 million (2022).
  • In the last 5 years, GoodRx Holdings' Non Operating Income surged by 3118.72% in 2021 and then plummeted by 4865.19% in 2024.
  • GoodRx Holdings' Non Operating Income (Quarter) stood at -$5.9 million in 2021, then decreased by 10.13% to -$6.5 million in 2022, then grew by 2.08% to -$6.3 million in 2023, then fell by 6.68% to -$6.8 million in 2024, then fell by 25.83% to -$8.5 million in 2025.
  • Its Non Operating Income stands at -$8.5 million for Q3 2025, versus -$7.2 million for Q2 2025 and -$6.7 million for Q1 2025.